Biocon Limited · NSE:BIOCON
Biocon — Investor Presentation (February 2025)
37 slides from Biocon's investor presentation, February 2025
Slide 1: Corporate Presentation: The Multiplier Effect
Corporate Presentation The Multiplier Effect MAXIMIZING VALUE
Slide 2: Biocon Group is a global biopharmaceuticals frontrunner
Biocon Group is a global biopharmaceuticals frontrunner committed to provide equitable access to high-quality, life-saving medicines to millions of patients worldwide 2
Slide 3: Our Vision & Values
Our Vision & Values VISION To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe. VALUES • Value Creation through Innovation & Differentiation • Quality through Compliance & Best Practices • Integrity & Ethica
Slide 4: Biocon Group At A Glance
Biocon Group At A Glance Strategic Priorities 16,300+ 120+ Countries where Biocon Sustainable Patient Total Employees1 Growth Centricity products are available 1,700+ 8 Drug Discovery Drug Development Patents1 Manufacturing sites People Core Capabilities Focus on Power Science 100+ 14 of Top 20 Manu
Slide 5: Our Business Evolution Over The Years
Our Business Evolution Over The Years FY1999 FY2004 FY2009 FY2015 FY2019 FY2024 People Revenue People Revenue Revenue People Revenue People Revenue People Revenue USD 5 USD 85 People USD 484 USD 820 USD 1.9 250 700+ 3,500+ USD 184 7,500+ 11,000+ 16,300+ mn mn mn mn mn bn 2005-2009 2023- 1978-1999 20
Slide 6: Our Global Presence
Biocon London, UK Our Global Presence Dublin, Ireland Mosta, Malta Biocon Delemont, Switzerland Biocon Delware, US T Biocon Biologics Bengaluru, India(HQ) New Jersey, US London, UK Dublin, Ireland T Biocon Biologics Bad Homburg, Germany Visakhapatnam, India New Jersey, US Biocon Biologics Hyderabad,
Slide 7: Leading Global, Diversified Biopharmaceuticals Group
Leading Global, Diversified Biopharmaceuticals Group Driving Greater Health Equity Through Affordable Healthcare Products & Services Differentiated and Well-Balanced Portfolio of Generics, Biosimilars, Novel Biologics and Research Services Ensuring Access Pushing Scientific Transforming Healthcare.
Slide 8: Generics Business
Generics Business
Slide 9: Generics
Generics APIs v Leadership in fermentation-based • 50+ APIs in portfolio Expanding portfolio to include APIs – Immunosuppressants, statins, • Serving 750+ API customers oncology-based HPAPIs and anti-infectives • Supplying to 100+ countries peptides, particularly GLP-1s FORMULATIONS v Vertically int
Slide 10: State-of-the-Art R&D and Manufacturing Capabilities
State-of-the-Art R&D and Manufacturing Capabilities • R&D staff: 400+ • 1st Generics Company to be approved for Liraglutide in an ICH or major regulated market • 7 Manufacturing sites (6 in India + 1 in U.S.) • 90+ cGMP approvals till date. • Key Technologies for APIs: Fermentation, Chemical Synthes
Slide 11: Balanced Portfolio of Generic APIs, Formulations
Balanced Portfolio of Generic APIs, Formulations APIs Generic Formulations Cardiovascular Cardiovascular (Atorvastatin, Dabigatran etc) Anti-Diabetics Anti-diabetic & Anti-obesity (GLP-1s: Liraglutide) Immunosuppressants Immunosuppressants (Tacrolimus, Mycophenolic Sodium) Oncology Oncology (Everoli
Slide 12: Generics Business At A Glance
Generics Business At A Glance 50+ 60+ 750+ 100+ APIs in portfolio Generic Pharma companies Countries reached Formulations in served commercially portfolio 7 90+ 8% 400+ Manufacturing cGMP approvals R&D investment as R&D Staff sites from international % of revenue regulatory agencies Note: Status as
Slide 13: Biosimilars Business
5S Biocon Biologics Biosimilars Business
Slide 14: End-to-End Capabilities Across the Biosimilars Value Chain
End-to-End Capabilities Across the Biosimilars Value Chain Research & Development Manufacturing Commercialization Cutting-edge science & technology State-of-the-art facilities with Commercial reach extending capabilities global-scale capacity across 120+ countries
Slide 15: Setting New Benchmarks in Global Biosimilars Industry
Setting New Benchmarks in Global Biosimilars Industry INSULINS mAbs\rPROTEINS 2004 2020 2014 2018 World’s 1st Pichia Pastoris 1st company from India to World’s 1st bTrastuzumab 1st company globally to technology-based rh-Insulin commercialize bGlargine launched in India get U.S. FDA approval for dev
Slide 16: Robust Biosimilars Pipeline Supports Medium-term Growth
Robust Biosimilars Pipeline Supports Medium-term Growth Comprehensive Product Portfolio Across Therapy Areas Unlocks a ~US$100 Bn Global Opportunity Therapy Area Oncology Immunology Diabetes Eye Health Bone Health Others Commercial / • bPegfilgrastim • bGlargine U100 • bAdalimumab • bTrastuzumab • r
Slide 17: Fully Integrated, Global-Scale Biologics Production Capacities
Fully Integrated, Global-Scale Biologics Production Capacities • 3 state-of-the-art manufacturing sites for insulins, mAbs & conjugated rProteins (2 India, 1 Malaysia) • 80+ cGMP approvals from 25+ regulators (including U.S. FDA & EMA) • Drug Substance, Drug Product & Devices capabilities • 300+ KL
Slide 18: Center of Excellence for Insulin Production in Johor, Malaysia
Center of Excellence for Insulin Production in Johor, Malaysia ▪ State-of-the-art integrated insulins manufacturing facility set up at an investment of over $350 million. ▪ Facility approved by U.S. FDA, EMA, NPRA (Malaysia), TGA (Australia), ANVISA (Brazil), etc. ▪ Investing an additional $250 mill
Slide 19: Strong Commercial Capabilities: Reach in 120+ Countries
Strong Commercial Capabilities: Reach in 120+ Countries Leveraging ‘Lab to Market’ Capabilities to Address Patients’ Needs Across Geographies Bad Homburg Product Development ✓ Biosimilars Value Chain Dublin ✓ Toronto Clinical Trials Bridgewater ✓ Cambridge London New Jersey Lyon Regulatory Athens Du
Slide 20: Biocon Biologics at a Glance
Biocon Biologics at a Glance Global Reach in Top 5 Top 15 80+ Diverse Global 120+ Global Insulins in Global cGMP Approvals Talent Pool of Countries Player1 Biomanufacturing Received from ~5,500 Capacity2 Key Regulatory People Agencies 390+ Portfolio 10 5+ mn Patents Comprises Approved Patients Serve
Slide 21: Research Services Business
Research Services Business
Slide 22: Research Services Business
Research Services Business A Global CRO and CDMO Offering Integrated Solutions Innovative R&D, Strong Technical Collaborations Manufacturing Expertise Service offerings incorporate Working with 400+ clients, including Expertise and capability to deliver cutting-edge technologies like CAR-T, 14 of th
Slide 23: Partnered with Global Leaders in Multiple Industry Segments
Partnered with Global Leaders in Multiple Industry Segments Note: Status as of March 2024
Slide 24: Syngene at a Glance
Syngene at a Glance 400+ >2 Mn 8500+ Active clients Square feet of Global Workforce Infrastructure 87 450+ >80% Recent client and Patents Green Power1 regulatory audits1 IP created for clients 1 For FY24
Slide 25: Novel Biologics Business
Novel Biologics Business
Slide 26: Novel Biologics
Novel Biologics • Clinical-stage biopharmaceutical company • Committed to bringing transformative bifunctional therapies for solid tumors • Lead asset is Ficerafusp alfa (BCA101), a first- in-class, dual-action, bifunctional EGFR/TGF- β antibody • Bicara starts trading on Nasdaq in September 2024: R
Slide 27: Financials
Financials
Slide 28: Biocon Group: Financial Highlights for FY24
Biocon Group: Financial Highlights for FY24 Rs Million Biocon: Business Revenue Mix FY24 YoY FY 24 FY 23 Revenue +35% 156,212 115,501 19% EBITDA +44% 41,642 28,876 Generics % margin 27% 25% 58% PBT Before Exceptional +29% 15,368 11,885 23% Biosimilars Items Research Services PBT +70% 15,252 8,971 Ne
Slide 29: Biocon Group: Financial Highlights for 9M FY25
Biocon Group: Financial Highlights for 9M FY25 Rs Million YoY% YoY% (Adj.) 9M FY 25 9M FY 24 Revenue +3% 120,160 116,555 EBITDA +2% 32,595 31,997 % margin 27% 27% PBT Before +9% 13,238 12,090 Exceptional Items PBT +16% 13,998 12,062 Figures above are rounded off to the nearest million; % based on ab
Slide 30: Environment, Social, Governance
Environment, Social, Governance
Slide 31: ESG: Going Beyond Financials to Have a Positive Impact
ESG: Going Beyond Financials to Have a Positive Impact Our ESG Strategy is Focused on ‘Unconditional Equity’ Improve access to Build an empowering Adapting to Operate with integrity, Enable underserved high-quality and inclusive sustainable business transparency and communities for therapeutics to d
Slide 32: Successfully Embedding Sustainable Practices Throughout Biocon's Operations
Successfully Embedding Sustainable Practices Throughout Biocon’s Operations • S&P Global ESG Score at 69 vs 63 last year • Environmental Dimension: Score: 76 | Industry max: 76 | Industry mean: 15 • Social Dimension: Score: 74 | Industry max: 76 | Industry mean: 23 • Governance & Economic Dimension:
Slide 33: ESG Awards & Recognitions
ESG Awards & Recognitions Enhanced FTSE4GOOD Index score to 3.6 from 3.2, Included in S&P Global 2024 Sustainability Yearbook surpassing the healthcare industry average of 2.3 and 2 years in a row biotech sub-industry average of 2.8 Included in DJSI EMs Index for 3 consecutive years ISS ESG Corporat
Slide 34: Corporate Social Responsibility
Corporate Social Responsibility Empowering Communities Biocon Foundation’s Programs Align with Schedule VII CSR Activities as Notified Under Section 135 of the Companies Act 2013 Specialist Camps ▪ NCD Camps Primary ▪ Geriatric Camps Healthcare ▪ Well Baby Camps ▪ Dental Camps eLAJ Smart Clinics: ~
Slide 35: Adding Value, Enhancing Skills
Adding Value, Enhancing Skills Center of Excellence for Advanced Learning in Applied Biosciences Education Partners: Claremont, California, USA Developing high-end talent for the Biotech sector PROGRAMS • Biocon-KGI Certificate Program in Biosciences • A combination of academic and • BITS Biocon Cer
Slide 36: People Equity: Ranked Among Top Global Pharma & Biotech Employers
People Equity: Ranked Among Top 10 Global Pharma & Biotech Employers Biocon (including Biocon Biologics) Ranked No. 9 in Top 20 Key Attributes SOCIAL INNOVATION RESPONSIBILITY EMPLOYEE LOYALTY Biocon Has Been On The Top 20 Global Biotech Employers List Since 2012 Note: Science Top Employer is a Top
Slide 37: Thank You
Thank You Icon Icon Logo, icon Description automatically generated Description automatically generated Description automatically generated www.biocon.com February 2025 Biocon Group Corporate Presentation, Developed and Released by Biocon Group Global Communications Team. Write to us at: BioconGroup.